Disruption of 3CLpro protease self-association by short peptides as a potential route to broad spectrum coronavirus inhibitors

被引:2
作者
ElSawy, Karim M. [1 ,2 ]
Alminderej, Fahad M. [1 ]
Caves, Leo S. D. [2 ]
机构
[1] Qassim Univ, Coll Sci, Dept Chem, Buraydah, Saudi Arabia
[2] Univ York, York Cross Disciplinary Ctr Syst Anal YCCSA, York, N Yorkshire, England
关键词
COVID-19; inhibitors; blind drug docking; 3CLpro dimerization; coronavirus inhibitors; RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR-DYNAMICS SIMULATION; FDA-APPROVED INHIBITORS; SARS-CORONAVIRUS; HOT-SPOTS; 3C-LIKE PROTEASE; MAIN PROTEASE; DOCKING; SARS-COV-2; RIBAVIRIN;
D O I
10.1080/07391102.2021.1996462
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Coronaviruses have posed a persistent threat to human health over the last two decades. Despite the accumulated knowledge about coronavirus-related pathogens, development of an effective treatment for its new variant COVID-19 is highly challenging. For the highly-conserved and main coronavirus protease 3CLpro, dimerization is known to be essential for its catalytic activity and thereby for virus proliferation. Here, we assess the potential of short peptide segments to disrupt dimerization of the 3CLpro protease as a route to block COVID-19 proliferation. Based on the X-ray structure of the 3CLpro dimer, we identified the SPSGVY126QCAMRP dodecapeptide segment as overlapping the hotspot regions on the 3CLpro dimer interface. Using computational blind docking of the peptide to the 3CLpro monomer, we found that the SPSGVY126QCAMRP peptide has favourable thermodynamic binding (DG 1/4 -5.93 kcal/mol) to the hotspot regions at the 3CLpro dimer interface. Importantly, the peptide was also found to preferentially bind to the hotspot regions compared to other potential binding sites lying away from the dimer interface (DDG=-1.31 kcal/mol). Docking of peptides corresponding to systematic mutation of the V125 and Y126 residues led to the identification of seven peptides, SPSGHAQCAMRP, SPSGVTQCAMRP, SPSGKPQCAMRP, SPSGATQCAMRP, SPSGWLQCAMRP, SPSGAPQCAMRP and SPSGHPQCAMRP, that outperform the wild-type SPSGVY126QCAMRP peptide in terms of preferential binding to the 3CLpro dimer interface. These peptides have the potential to disrupt 3CLpro dimerization and therefore could provide lead structures for the development of broad spectrum COVID19 inhibitors.
引用
收藏
页码:13901 / 13911
页数:11
相关论文
共 68 条
  • [1] Benchmarking of different molecular docking methods for protein-peptide docking
    Agrawal, Piyush
    Singh, Harinder
    Srivastava, Hemant Kumar
    Singh, Sandeep
    Kishore, Gaurav
    Raghava, Gajendra P. S.
    [J]. BMC BIOINFORMATICS, 2019, 19 (Suppl 13)
  • [2] Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers
    Al-Tawfiq, Jaffar A.
    Zumla, Alimuddin
    Memish, Ziad A.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2014, 27 (05) : 411 - 417
  • [3] Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
    Al-Tawfiq, Jaffar A.
    Momattin, Hisham
    Dib, Jean
    Memish, Ziad A.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 20 : 42 - 46
  • [4] Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro
    Alamri, Mubarak A.
    ul Qamar, Muhammad Tahir
    Mirza, Muhammad Usman
    Bhadane, Rajendra
    Alqahtani, Safar M.
    Muneer, Iqra
    Froeyen, Matheus
    Salo-Ahen, Outi M. H.
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (13) : 4936 - 4948
  • [5] Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs
    Anand, K
    Ziebuhr, J
    Wadhwani, P
    Mesters, JR
    Hilgenfeld, R
    [J]. SCIENCE, 2003, 300 (5626) : 1763 - 1767
  • [6] Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain
    Anand, K
    Palm, GJ
    Mesters, JR
    Siddell, SG
    Ziebuhr, J
    Hilgenfeld, R
    [J]. EMBO JOURNAL, 2002, 21 (13) : 3213 - 3224
  • [7] Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream
    Arkin, MR
    Wells, JA
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) : 301 - 317
  • [8] Programmed ribosomal frameshifting in decoding the SARS-CoV genome
    Baranov, PV
    Henderson, CM
    Anderson, CB
    Gesteland, RF
    Atkins, JF
    Howard, MT
    [J]. VIROLOGY, 2005, 332 (02) : 498 - 510
  • [9] Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
    Barnard, Dale L.
    Kumaki, Yohichi
    [J]. FUTURE VIROLOGY, 2011, 6 (05) : 615 - 631
  • [10] Anatomy of hot spots in protein interfaces
    Bogan, AA
    Thorn, KS
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1998, 280 (01) : 1 - 9